Mohammed A Abu-Ameerh1, Hanan D Jafar2,3, Maram H Hasan2, Muawyah D Al Bdour1, Mohammed Msallam1, Osama H Ababneh1, Dana M Alhattab2, Ban Al-Kurdi2, Abdelhalim A Awidi3, Abdalla S Awidi4,5. 1. Department of Ophthalmology, School of Medicine, The University of Jordan, Amman, Jordan. 2. Cell Therapy Center, The University of Jordan, Amman, Jordan. 3. Department of Anatomy and Histology, School of Medicine, The University of Jordan, Amman, Jordan. 4. Cell Therapy Center, The University of Jordan, Amman, Jordan. aabbadi@ju.edu.jo. 5. Department of Medicine, School of Medicine, The University of Jordan, Amman, Jordan. aabbadi@ju.edu.jo.
Abstract
PURPOSE: To study the use of autologous platelet lysate prepared in a standardized method for the healing of persistent corneal epithelial defects (PED). STUDY DESIGN: Clinical and experimental investigation. METHODS: In this prospective pilot study (ClinicalTrials.gov identifier NCT02979912), ten patients with a PED duration of a minimum 14 days were included. Autologous platelet lysate was prepared in a standardized methodology. Repeated freeze-thaw cycles were used to lyse the platelets. Patients were advised to apply the eye drops four times a day and were evaluated at baseline and on days 7, 14, 21, 28. RESULTS: No adverse events were reported due to the use of undiluted autologous platelet lysate. A total of 70% of patients had complete re-epithelialization within 28 days. Of these, 40% healed within 14 days (effective group) and 30% within 28 days (partially effective group). CONCLUSIONS: Undiluted autologous platelet lysate, prepared according to a standardized methodology, is a safe and effective adjunct therapy for the treatment of PED.
PURPOSE: To study the use of autologous platelet lysate prepared in a standardized method for the healing of persistent corneal epithelial defects (PED). STUDY DESIGN: Clinical and experimental investigation. METHODS: In this prospective pilot study (ClinicalTrials.gov identifier NCT02979912), ten patients with a PED duration of a minimum 14 days were included. Autologous platelet lysate was prepared in a standardized methodology. Repeated freeze-thaw cycles were used to lyse the platelets. Patients were advised to apply the eye drops four times a day and were evaluated at baseline and on days 7, 14, 21, 28. RESULTS: No adverse events were reported due to the use of undiluted autologous platelet lysate. A total of 70% of patients had complete re-epithelialization within 28 days. Of these, 40% healed within 14 days (effective group) and 30% within 28 days (partially effective group). CONCLUSIONS: Undiluted autologous platelet lysate, prepared according to a standardized methodology, is a safe and effective adjunct therapy for the treatment of PED.